Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 326 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hemoglobin Clear all

Conditions: Elevated Levels of Carboxyhemoglobin
Interventions: Pulse Co-Ox; Device
Lead sponsor: Nonin Medical, Inc; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tetrahydrobiopterin (BH4), Antioxidant Cocktail; Drug · Dietary Supplement
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Sickle Cell Disease, Thalassemia
Interventions: Etavopivat tablets; Drug
Lead sponsor: Forma Therapeutics, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 14
States / cities: Cerritos, California • Los Angeles, California • Oakland, California + 9 more

Conditions: Anemia
Interventions: Jobelyn™, Placebo; Dietary Supplement
Lead sponsor: Natural Immune Systems Inc; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Klamath Falls, Oregon

Conditions: Trauma
Interventions: Radical-7 Pulse CO-Oximeter and sensor; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 16 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteoarthritis
Interventions: Total knee arthroplasty; Procedure
Lead sponsor: Exactech; Industry
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Peripheral Neuropathy, Chemotherapy-induced
Interventions: PROCRIT 40,000 IU QW, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 28
States / cities: Mobile, Alabama • Little Rock, Arkansas • Alhambra, California + 25 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Diabetes MAP Intervention; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin, Placebo, Sitagliptin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 678 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 24
States / cities: Phoenix, Arizona • Concord, California • Greenbrae, California + 21 more

Conditions: Anemia, End Stage Renal Disease
Interventions: Individualized Anemia Mangement Protocol; Other
Lead sponsor: Michael Germain; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Chicopee, Massachusetts

Conditions: Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions: Vadadustat, Darbepoetin alfa; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 54
States / cities: Huntsville, Alabama • Mesa, Arizona • Anaheim, California + 45 more

Conditions: Anemia, Sickle Cell
Interventions: Glutamine, Placebo; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years to 18 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Anaemia
Interventions: GSK1278863, rhEPO; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 25
States / cities: Peoria, Arizona • Azusa, California • La Mesa, California + 21 more

Conditions: Healthy
Interventions: Rainbow adhesive adult/pediatric sensor, Rainbow adhesive adult/neonatal sensor; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Irvine, California

Conditions: Diabetes Mellitus, Vitamin D Deficiency
Interventions: Vitamin D; Dietary Supplement
Lead sponsor: Ascension Health; Industry
Eligibility: 34 Years to 69 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Anemia in Incident Dialysis Patients
Interventions: Roxadustat, Epoetin Alfa; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 1,043 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 30
States / cities: Chula Vista, California • La Mesa, California • San Diego, California + 25 more

Conditions: Type 2 Diabetes
Interventions: automated telephone intervention vs. usual care; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 55 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Steroid-refractory Diamond-Blackfan Anemia (DBA)
Interventions: Bitopertin; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 1 Diabetes Mellitus
Interventions: CloudConnect Report, Will not receive a CloudConnect Report; Other
Lead sponsor: University of Virginia; Other
Eligibility: 12 Years to 17 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Bleeding, Acute Blood Loss Anemia
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Elevated Levels of Carboxyhemoglobin and Methemoglobin
Interventions: Elevated levels of carboxyhemoglobin; Other
Lead sponsor: Nonin Medical, Inc; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hemoglobin, Stem Cell Transplant, Aplastic Anemia
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 7 Years to 45 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes Treated With Insulin
Interventions: Insulin glargine, NovoLog, Insulin Fiasp, Standard carbohydrate diet; Drug · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: CKD Anemia
Interventions: Roxadustat, Placebo; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 922 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 55
States / cities: Huntsville, Alabama • Tempe, Arizona • Alhambra, California + 48 more

Search by objective public record fields.

Dysfunctional Hemoglobin CO-ox

Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)

A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

Efficacy of Jobelyn™ Consumption on Hemoglobin Levels in a Borderline Anemic Population

Evaluation of Non-Invasive Hemoglobin in Trauma Patients

Standard Total Knee Arthroplasty Using Platelet Rich Plasma (PRP)

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

The Diabetes Medication Adherence Promotion Intervention Trial

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

The Effect of Epogen and Venofer Dosing Management on Hemoglobin Stability

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Trial of Oral Glutamine in Patients With Sickle Cell Anemia

A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)

Comparison of Noninvasive Hemoglobin Disposable Sensors

Effect of Vitamin D Supplementation on Hemoglobin A1c

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants

Impact of an Automated Telephone Intervention on Glycosylated Hemoglobin (HbA1c) in Type 2 Diabetes

Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia

CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management

Continuous Hemoglobin Monitoring: Detection of Acute Blood Loss - Accurate, Timely and Cost-effective

Dysfunctional Hemoglobin

Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease

Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus

A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis